Bavarian Nordic A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVNRY research report →
Price Chart
About the company
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine.
- CEO
- Tarja Stenvall
- IPO
- 2013
- Employees
- 1,795
- HQ
- Hellerup, CR, DK
Get TickerSpark's AI analysis on BVNRY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.84B
- P/E
- 20.48
- Fwd P/E
- 2.41
- PEG
- -0.34
- P/S
- 2.93
- P/B
- 1.37
- EV/EBITDA
- 9.22
- Div Yield
- 0.00%
- Gross Margin
- 50.04%
- Op Margin
- 18.34%
- Net Margin
- 14.24%
- ROE
- 6.86%
- ROIC
- 5.79%
Latest fiscal year · YoY change
- Revenue
- $5.93B+3.8%
- Gross Profit
- $2.81B-0.2%
- Op Income
- $885.42M
- Net Income
- $1.32B+33.9%
- EPS
- $5.66+34.7%
- OCF Growth
- +34.2%
- FCF Growth
- +823.0%
- 52W High
- $12.72
- 52W Low
- $8.67
- 50D MA
- $11.60
- 200D MA
- $10.25
- Beta
- 0.94
- RSI (14)
- 50
- Avg Volume
- 2.99K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Bavarian Nordic posted another strong quarter, with Travel Health and Public Preparedness both performing well, EBITDA margins remaining unusually high, and management reaffirming full-year 2026 guidance.· November 13, 2026
- 9M revenue was just under DKK 4.9 billion, up 2% reported and over 9% organic after adjusting for discontinued partnerships and FX.
- EBITDA margin was close to 35% for the 9 months and 34.4% in Q3, helped by mix and timing, despite some manufacturing disruption.
- Travel Health was the main growth engine, with 32% growth in Q3 and 34% for 9 months adjusted for discontinued partner business, driven by rabies, Vimkunya and TBE.
- Public Preparedness remained on track at about DKK 1.9 billion in Q3, and the company has already secured around DKK 2.4 billion for 2026 and around DKK 900 million for 2027.
- Management left 2026 guidance unchanged: revenue of around DKK 6.1 billion, including approximately DKK 4 billion from Travel Health, and EBITDA margin of around 32%.
For the first 9 months of 2026, revenue was just under DKK 4.9 billion, reported growth of 2%, and organic growth was over 9% after adjusting for discontinued partnerships and FX. Q3 gross margin was 52%, up a couple of percentage points year over year, and Q3 EBITDA margin was 34.4%; on a 9-month basis EBITDA margin was close to 35% and EBITDA was DKK 1.7 billion. Q3 cash flow from operating activities was DKK 809 million, free cash flow was more than DKK 500 million, and net cash flow after financing activities was DKK 372 million. Travel Health grew 22% in Q3 and 24% for 9 months, while Public Preparedness was in line with expectations and above its annual base level. Full-year 2026 guidance was maintained at revenue of around DKK 6.1 billion, with approximately DKK 4 billion from Travel Health and an EBITDA margin of around 32%; management also reiterated 2026 public preparedness revenue of DKK 2.5 billion and mentioned a DKK 3.4 billion Travel Health outlook.
Tarja Stenvall used the call to frame the quarter as a strong starting point for her tenure and said she wants to sharpen the company’s strategy around where to focus investment and growth. She highlighted four priorities: capture more of the travel health opportunity, deepen government partnerships in Public Preparedness, build a more efficient manufacturing and supply network, and consider organic and inorganic growth. Her tone was constructive and confident, but also reflective, emphasizing that she is still in a listening and learning phase and will share strategic priorities in the first half of 2027.
Henrik Juuel described the quarter as very strong and said the company is seeing exceptional momentum in Travel Health, especially rabies, with U.S. rabies revenue growth at 36% for 9 months and monthly growth accelerating to around 50%. He noted Q3 gross profit of 52%, said EBITDA margin of 34.4% was boosted by mix but also compared favorably with last year even before the DKK 810 million priority review voucher effect, and pointed to DKK 809 million operating cash flow in the quarter. He also said the company ended with nearly DKK 3 billion of cash despite buybacks, started a second share repurchase tranche of up to DKK 150 million, and kept the Public Preparedness base business guidance at DKK 1.5 billion to DKK 2 billion while acknowledging 2026 is tracking above that level at DKK 2.5 billion.
Analysts pressed on the implied Q4 slowdown in Travel Health, and management said the full-year guide is approximate, seasonality matters, and Q4 EBITDA is expected to be lower due to lower revenue and back-end loaded R&D and sales and marketing spend. Questions on Vimkunya focused on slower U.S. uptake; management said the U.S. uses a very conservative outbreak definition and has not yet confirmed the ACIP recommendation in MMWR, which is creating temporary purchasing hesitation, while Europe—especially Germany—has exceeded expectations. On capital allocation and M&A, management said buybacks can coexist with investment and M&A, but they remain selective and will outline a sharpened strategy and capital allocation approach in the first half of 2027. Analysts also asked about rabies and capacity; management said wholesaler inventory can amplify growth in a rapidly expanding market, and they are confident current manufacturing adjustments can support expected 2027 demand, though more investment may be needed later if U.S. rabies growth remains strong.
The bull case from this call is that Bavarian Nordic is converting strong demand in rabies and an encouraging launch of Vimkunya into above-target profitability and cash generation. Management also sounded confident that market demand is broadening, especially in the U.S. rabies market and in chikungunya as the disease spreads into more geographies, while Public Preparedness is adding multi-year contracting visibility.
The main risks discussed were the unpredictable pace of rabies demand, which management said is difficult to forecast and may require future manufacturing investment, and the slower-than-expected U.S. launch of Vimkunya due to conservative CDC/MMWR processes. TBE also remained challenged by shelf-life and supply issues earlier in the year, and management acknowledged that Q4 will be seasonally weaker with lower EBITDA margin and heavier investment spending.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 33.6%
- Shares Outstanding
- 240.07M
- Float Shares
- 80.59M
Our BVNRY coverage
Recent articles, reports, and earnings notes.
No research on BVNRY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BVNRY report →Bavarian Nordic A/S (BVNRY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 13
Bavarian Nordic beats Q3 revenue expectations
reuters.com · Nov 13
Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government
reuters.com · Nov 2
Bavarian Nordic donates 75,000 mpox vaccine doses to global emergency stockpile
reuters.com · Oct 27
Bavarian Nordic (OTCMKTS:BVNRY) Shares Break Above 50 Day Moving Average – What’s Next?
defenseworld.net · Oct 20
Bavarian Nordic (OTCMKTS:BVNRY) Sees Significant Decrease in Short Interest
defenseworld.net · Sep 30
Bavarian Nordic A/S (BVNRY) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 21
Global warming widens spread of TBE, chikungunya, Bavarian Nordic boss says
reuters.com · Aug 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.